precisionrxdx.com Open in urlscan Pro
75.2.60.5  Public Scan

Form analysis
1 forms found in the DOM

POST /success

<form action="/success" class="px-6 sm:pb-32 md:pb-24 md:pt-20 lg:px-8 lg:py-48 md:flex-1" method="POST"><input type="hidden" name="form-name" value="form 1"> <input type="hidden" name="subject" data-remove-prefix=""
    value="Contact Request from PrecisionRxDx.com">
  <div class="mx-auto max-w-xl lg:mr-0 lg:max-w-lg">
    <div class="grid grid-cols-1 gap-x-8 gap-y-6 sm:grid-cols-2">
      <div> <label for="name" class="block text-sm leading-6">Name</label>
        <div class="mt-2.5"> <input type="text" name="name" id="name" required="required" autocomplete="name"
            class="block w-full rounded-md border-0 bg-white px-3.5 py-2 shadow-sm ring-1 ring-inset ring-brand-blue-dark-base focus:ring-2 focus:ring-inset focus:ring-brand-blue-500 sm:text-sm sm:leading-6"> </div>
      </div>
      <div> <label for="last-name" class="block text-sm leading-6">Last name</label>
        <div class="mt-2.5"> <input type="text" name="last-name" id="last-name" required="required" autocomplete="family-name"
            class="block w-full rounded-md border-0 px-3.5 py-2 shadow-sm ring-1 ring-inset ring-brand-blue-dark-base focus:ring-2 focus:ring-inset focus:ring-brand-blue-500 sm:text-sm sm:leading-6"> </div>
      </div>
      <div class="sm:col-span-2"> <label for="email" class="block text-sm leading-6">Email</label>
        <div class="mt-2.5"> <input type="email" name="email" id="email" required="required" autocomplete="email"
            class="block w-full rounded-md border-0 px-3.5 py-2 shadow-sm ring-1 ring-inset ring-brand-blue-dark-base focus:ring-2 focus:ring-inset focus:ring-brand-blue-500 sm:text-sm sm:leading-6"> </div>
      </div>
      <div class="sm:col-span-2"> <label for="phone-number" class="block text-sm leading-6">Phone number (optional)</label>
        <div class="mt-2.5"> <input type="tel" name="phone-number" id="phone-number" autocomplete="tel"
            class="block w-full rounded-md border-0 px-3.5 py-2 shadow-sm ring-1 ring-inset ring-brand-blue-dark-base focus:ring-2 focus:ring-inset focus:ring-brand-blue-500 sm:text-sm sm:leading-6"> </div>
      </div>
      <div class="sm:col-span-2"> <label for="message" class="block text-sm leading-6">Message</label>
        <div class="mt-2.5"> <textarea name="message" id="message" rows="4" required="required"
            class="block w-full rounded-md border-0 px-3.5 py-2 shadow-sm ring-1 ring-inset ring-brand-blue-dark-base focus:ring-2 focus:ring-inset focus:ring-brand-blue-500 sm:text-sm sm:leading-6"></textarea> </div>
      </div>
    </div>
    <div class="mt-8"> <button type="submit"
        class="rounded-md bg-brand-blue-dark-base text-white px-12 py-2.5 text-center tracking-wider font-semibold shadow-sm hover:bg-brand-green-500 focus-visible:outline focus-visible:outline-2 focus-visible:outline-offset-2 focus-visible:outline-brand-blue-500 transition-colors">
        Send </button> </div>
  </div>
</form>

Text Content

Precision Rx-Dx Inc.


SUPPORTING THE IMPLEMENTATION OF PRECISION MEDICINE.

Precision Rx-Dx Inc. is an international consultancy, based in Canada, formed to
support companies during launch of their Precision Medicines and the associated
biomarkers.

Engage our Experts Today


Providing deep expertise to adapt regional strategies for companion diagnostics
and biomarkers to optimize launches of precision medicines

Our focus is to provide consultation and support to our clients in refining
their global strategies as well as building local market and organizational
readiness. Our team of experts have an extensive knowledge of the CDx and
biomarker landscape and the rapidly evolving policies and practices.

This ensures a robust launch and accelerated adoption of both the targeted
therapeutic and the associated biomarker.


PROVIDING BEST-PRACTICE BIOMARKER LAUNCH EXPERTISE FROM STRATEGY DEVELOPMENT TO
HANDS-ON TEST IMPLEMENTATION SUPPORT

Precision’s programs are developed to address the multidisciplinary requirement
of this field and we are very experienced in facilitating dialogue and
stakeholder collaboration to manage change in the marketplace.

Many of Precision’s programs culminate in the development of best practice
publications, including clinical and testing algorithms for new companion
diagnostics and biomarkers.


OUR TEAM

Our core team comprises seasoned experts many with over 25 years of experience
in diagnostic and/or pharmaceutical development. We are champions in
facilitating dialogue and stakeholder collaboration to manage change and drive
progress in the marketplace.

Our core team cover the following areas:

 * Education and consultation service on reimbursement
 * Precision medicine and biomarker education and program management
 * Strategic, scientific, and diagnostic advice and consultation
 * Medical writing for scientific publications


PRINCIPALS AND FOUNDERS


 * MONETTE GREENWAY, BSC., C. DIR.
   
   Principal and Co-Founder
   
   Educated in genetic engineering and biotechnology, Monette’s career has
   centered on the development and successful market adoption of life science
   and diagnostic innovation. Monette has lived and worked internationally with
   growth mandates in the pharma biomarker development area, and hospital and
   community lab sectors. With over 25 years of executive experience her past
   roles include global President/Vice President positions with Thermo Fisher
   Scientific and Executive Commercial/Government relations’ roles with LifeLabs
   Medical Laboratories, Strategic Diagnostics and Mount Sinai Services.


 * ANN HUMPHREYS, BSC., MBA.
   
   Principal and Co-Founder
   
   Ann has over 30 years of executive experience in the healthcare industry and
   brings hands-on market launch expertise and knowledge across many therapeutic
   and diagnostic categories. Ann started her career with J&J at Ortho
   Diagnostics here in Canada and was responsible for the development and launch
   of new diagnostic products both in Canada and internationally. Her extensive
   pharmaceutical experience includes her role on the Executive Management Board
   of Janssen-Ortho as VP Marketing and Sales, Biotech/Oncology and New Product
   Development. Ann was responsible for the launch of many speciality
   therapeutics products.


PUBLICATIONS

Our work speaks through our contributions to best practice publications and
clinical testing algorithms. Explore our recent thought leadership support in
the field of Precision Medicine.

 * Rendon RA, Selvarajah S, Wyatt AW, et al.
   "2023 Canadian Urological Association guideline: Genetic testing in prostate
   cancer"
   Can Urol Assoc J 2023; 17(10): 314-25
   Read 2023 Canadian Urological Association guideline: Genetic testing in
   prostate cancer Publication
 * Black, P. C. et al.
   "Optimizing management of advanced urothelial carcinoma: A review of emerging
   therapies and biomarker-driven patient selection."
   Can Urol Assoc J., E373-E382
   Read Optimizing management of advanced urothelial carcinoma: A review of
   emerging therapies and biomarker-driven patient selection. Publication
 * Cheung, C. C. et al and Canadian Association of Pathologists-Association
   Canadienne Des Pathologistes' National Standards Committee for High
   Complexity (2019)
   "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in
   Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian
   Association of Pathologists-Association Canadienne Des Pathologistes
   (CAP-ACP)."
   Appl Immunohistochem Mol Morphol 27(10): 699-714
   Read Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in
   Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian
   Association of Pathologists-Association Canadienne Des Pathologistes
   (CAP-ACP). Publication
 * Stockley, T. et al.
   "Evidence-based best practices for EGFR T790M testing in lung cancer in
   Canada."
   Curr Oncol 25(2): 163-169
   Read Evidence-based best practices for EGFR T790M testing in lung cancer in
   Canada. Publication
 * Torlakovic, E., et al.
   "“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis
   of diagnostic accuracy."
   Mod Pathol, 4-17
   Read “Interchangeability” of PD-L1 immunohistochemistry assays: a
   meta-analysis of diagnostic accuracy. Publication
 * Cheema, P., et al.
   "Consensus Recommendations for Optimizing Biomarker Testing to Identify and
   Treat Advanced EGFR-Mutated NSCLC."
   Curr Oncol 27(6)
   Read Consensus Recommendations for Optimizing Biomarker Testing to Identify
   and Treat Advanced EGFR-Mutated NSCLC. Publication
 * Tierens, A., et al.
   "Consensus Recommendations for MRD Testing in Adult B-Cell Acute
   Lymphoblastic Leukemia in Ontario"
   Curr. Oncol. 28(2), 1376-1387
   Read Consensus Recommendations for MRD Testing in Adult B-Cell Acute
   Lymphoblastic Leukemia in Ontario Publication
 * Ionescu, D., et al.
   "Consensus Recommendations to Optimize Testing for New Targetable Alterations
   in Non-Small Cell Lung Cancer"
   Curr. Oncol. 29(7), 4981-4997
   Read Consensus Recommendations to Optimize Testing for New Targetable
   Alterations in Non-Small Cell Lung Cancer Publication
 * Selvarajah, S., et al
   "Recommendations for the implementation of genetic testing for metastatic
   prostate cancer patients in Canada"
   CUAJ 2022, 16(10)
   Read Recommendations for the implementation of genetic testing for metastatic
   prostate cancer patients in Canada Publication

Name

Last name

Email

Phone number (optional)

Message

Send


CONTACT US

We are committed to responding promptly and efficiently to your needs.

Email info@precisionrxdx.com
Address Toronto, ON
LinkedIn

© 2024 Precision Rx-Dx, Inc. All rights reserved.